midazolam has been researched along with warfarin in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.28) | 18.2507 |
| 2000's | 26 (33.33) | 29.6817 |
| 2010's | 40 (51.28) | 24.3611 |
| 2020's | 11 (14.10) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barnard, L; Birkholtz, LM; Botha, M; Brunschwig, C; Burrows, JN; Chibale, K; Churchyard, A; Coetzer, TL; Denti, P; Egan, TJ; Laing, L; Lauterbach, S; Machado, M; Ndubi, F; Njogu, PM; Njoroge, M; Nondaba, S; Okombo, J; Prudêncio, M; Reader, J; Singh, K; Wiesner, L; Wilkinson, C; Wittlin, S; Yeates, C | 1 |
| Abd Rabo Moustafa, MM; Abdelghany, TM; Eissa, IH; Elshafeey, A; Mayhoub, AS; Mohammad, H; Qassem, OA; Seleem, MN; Younis, W | 1 |
| Chibale, K; Egan, TJ; Hunter, R; Joshi, MC; Ndove, J; Nsumiwa, S; Okombo, J; Taylor, D; Wiesner, L | 1 |
| Crespi, CL; Davitt, CM; Hu, M; Huang, SM; Li, Y; Penman, BW; Thummel, K | 1 |
| Bu, HZ; Knuth, K; Magis, L; Teitelbaum, P | 1 |
| Fujita, K; Kamataki, T; Nakayama, K; Nohmi, T; Tsuruma, K; Yamada, M; Yamazaki, Y | 1 |
| Chiba, K; Kobayashi, K; Shimada, N; Urashima, K | 1 |
| Cantrell, VE; Eckstein, J; Hall, SD; Hamman, MA; Jones, DR; Ring, BJ; Ruterbories, K; Williams, JA; Wrighton, SA | 1 |
| Ali, EM; Bini, EJ; Choung, RJ; Firoozi, B; Osman, M; Weinshel, EH | 1 |
| Adedoyin, A; Caserta, KA; Jones, SS; Laws, K; Saraswat, LD; Wei, D | 1 |
| Bertino, JS; Chainuvati, S; Gaedigk, A; Kashuba, AD; Kearns, GL; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Zhang, Y | 1 |
| Bertino, JS; Gaedigk, A; Kashuba, AD; Kearns, G; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Shelepova, T; Victory, J; Zhang, Y | 1 |
| Adkison, KK; Berrey, MM; Bertino, JS; Borland, J; Fang, L; Johnson, BM; Lou, Y; Nafziger, AN; Piscitelli, SC; Song, IH | 1 |
| Baxter-Meheux, F; Blake, MJ; Eron, JJ; Gaver, VE; Kashuba, AD; Klein, CE; Patterson, KB; Rezk, NL; Rublein, JC; Yeh, RF | 1 |
| Balani, SK; Gallegos, R; Gan, LS; Li, P; Lu, C; Miwa, GT; Uttamsingh, V; Xia, CQ | 1 |
| Booth-Genthe, C; Carr, B; Fang, Y; Lu, P; Norcross, R; Rodrigues, AD; Rushmore, T; Shou, M | 1 |
| Chaudhary, A; Drijfhout, WJ; Garner, RC; Jochemsen, R; Kneer, J; Kuhnz, W; Lappin, G; Oosterhuis, B; Rowland, M | 1 |
| Carter, GT; Di, L; Kerns, EH; Li, SQ | 1 |
| Backman, JT; Lilja, JJ; Neuvonen, PJ | 1 |
| Ashton, M; Asimus, S; Elsherbiny, D; Hai, TN; Huong, NV; Jansson, B; Petzold, MG; Simonsson, US | 1 |
| Kushida, K | 1 |
| Boulenc, X; Brian, W; Donazzolo, Y; Poitiers, F; Santoni, A; Turpault, S; Van Horn, R | 1 |
| Iida, H; Kozawa, O; Tanabe, K | 1 |
| Iwadate-Iwata, E; Kaneko, K; Kato, I; Onoue, M; Suzuki, K; Uchida, K | 1 |
| Bridges, AS; Connolly, EA; González-Pérez, V; Paine, MF; Wienkers, LC | 1 |
| Doogue, MP; Jensen, BP; Patel, F; Polasek, TM; Sorich, MJ; Wiese, MD | 1 |
| Iwasaki, K; Izumi, H; Kusumoto, S; Mogi, M; Murayama, N; Shimizu, M; Takehara, H; Toda, A; Utoh, M; Yamazaki, H | 1 |
| Brennan, BJ; Chang, L; Giraudon, M; Kulkarni, R; Morcos, PN; Shulman, N; Smith, PF; Tran, JQ | 1 |
| Aharchi, F; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Onkelinx, J; Peeters, M; Stevens, T; Van Solingen-Ristea, RM | 1 |
| Bank, PC; Beijnen, JH; Hendrikx, JJ; Maas-Bakker, RF; Meijerman, I; Mooiman, KD; Rosing, H; Schellens, JH | 1 |
| Ikeda, K; Kim, S; Koyanagi, T; Murayama, N; Nakanishi, Y; Uehara, S; Uno, Y; Utoh, M; Yamaura, Y; Yamazaki, H; Yano, K | 1 |
| Ballow, C; Battegay, M; Chan, TS; Cooper, C; Girlich, B; Haschke, M; Kashuba, AD; Kort, J; Lang, B; Li, Y; O'Brien, D; Sabo, JP; Seibert, E; Ting, N; Tweedie, D; Zhang, W | 1 |
| Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathôt, RA; Romijn, JA; Soeters, MR; van Nierop, FS | 1 |
| Chen, D; Davis, HM; de Vries, DE; Leon, F; Marciniak, SJ; Xu, Z; Zhou, H; Zhuang, Y | 1 |
| Murayama, N; Shida, S; Shimizu, M; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Inoue, T; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Shida, S; Yamazaki, H | 1 |
| Kawano, M; Mitsui, M; Sasaki, E; Shimizu, M; Suemizu, H; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Lei, D; Li, X; Liu, Y; Lu, J; Wei, J; Yan, S | 1 |
| Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathot, RA; Romijn, JA | 1 |
| Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA; van Schaik, RHN | 1 |
| Bedwell, DW; Hall, SD; Mohutsky, MA; Rougée, LRA; Ruterbories, KJ | 1 |
| Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Edwards, JE; Eliot, L; Karan, S; MacConell, L; Parkinson, A | 1 |
| Gajee, R; Papadopoulos, KP; Puzanov, I; Strickler, JH; Tachibana, M; Wang, Y; Zahir, H | 1 |
| Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA | 1 |
| den Adel, M; Garcia-Hernandez, A; Groenendaal-van de Meent, D; Katashima, M; Kato, K; Kusawake, T; Ohtsu, Y; Takada, A | 1 |
| Gong, Z; Huang, J; Li, Y; Liu, C; Liu, T; Lu, Y; Pan, J; Sun, J; Wang, Y; Zheng, J; Zheng, L | 1 |
| Liu, L; Liu, X; Tang, X; Wang, S; Xu, J; Yang, T; Zhang, J | 1 |
| Bailey-Smith, C; Bodrug, I; Cheng, A; Glasgow, XS; Hussain, A; Iwamoto, M; Khalilieh, S; Levine, V; Martinho, M; Mekokishvili, L; Montgomery, D; Shaw, PM | 1 |
| Camez, A; Cheng, L; Ignatenko, S; Khatri, A; Othman, AA; Pang, Y | 1 |
| Ducray, PS; Endo-Tsukude, C; Gardner, I; Gill, KL; Hatley, OJ; Machavaram, KK; Parrott, N; Terao, K | 1 |
| Chung, JY; Hatley, O; Kim, Y; Lee, H; Lee, HA; Rhee, SJ; Yi, S; Yoon, S; Yu, KS | 1 |
| Enejosa, JV; Feng, T; Fisniku, O; Mohamed, MF; Othman, AA | 1 |
| Bairlein, M; Gerisch, M; Heinig, R; Loewen, S; Nagelschmitz, J | 1 |
| Chen, D; Piantone, A; Sharma, A; Shu, C; Xu, Y; Xu, Z; Zhou, H; Zhu, Y; Zhuang, Y | 1 |
| Mohamed, MF; Othman, AA; Sathe, AG | 1 |
| Kawaguchi, A; Nakamura, T; Shimizu, H | 1 |
| de Braud, F; De Castro Carpeño, J; de Miguel Luken, MJ; Hurtado, FK; Lau, YY; Mau-Sorensen, M; McCulloch, T; Scott, J; Wang, D | 1 |
| Henderson, LM; Ragueneau-Majlessi, I; Steinbronn, CE; Yeung, CK; Yu, J | 1 |
| Chen, Y; Miao, X; Wang, L; Zhou, H; Zhou, W | 1 |
| Hoch, M; Hourcade-Potelleret, F; Sengupta, T | 1 |
| Newman, EM; Rowland, A | 1 |
| Fan, Y; Feng, S; Fu, M; Gu, F; Huang, J; Lin, H; Lu, Z; Luo, L; Shen, K; Wu, B | 1 |
4 review(s) available for midazolam and warfarin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Topics: Adult; Biological Availability; Caffeine; Case-Control Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytokines; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Models, Biological; Patient Acuity; Psoriasis; Warfarin; Young Adult | 2021 |
Analysis of Drug-Drug Interaction Labeling Language and Clinical Recommendations for Newly Approved Drugs Evaluated With Digoxin, Midazolam, and S-Warfarin.
Topics: Digoxin; Drug Interactions; Humans; Language; Midazolam; Pharmaceutical Preparations; Product Labeling; Warfarin | 2021 |
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorphan; Metoprolol; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Rosiglitazone; Warfarin | 2022 |
23 trial(s) available for midazolam and warfarin
| Article | Year |
|---|---|
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Topics: Acetyltransferases; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Genotype; Humans; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Phosphodiesterase Inhibitors; Reproducibility of Results; Vitamins; Warfarin; Xanthine Oxidase | 2003 |
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Genotype; Humans; Midazolam; Norgestrel; Omeprazole; Therapeutic Equivalency; Vitamin K; Warfarin; Xanthine Oxidase | 2005 |
Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; CCR5 Receptor Antagonists; Dextromethorphan; Diketopiperazines; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Omeprazole; Piperazines; Spiro Compounds; Warfarin | 2006 |
Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Area Under Curve; Carbon Radioisotopes; Chromatography, Liquid; Cross-Over Studies; Diazepam; Dose-Response Relationship, Drug; Drug Monitoring; Erythromycin; Estradiol; Female; GABA Modulators; Humans; Injections, Intravenous; Male; Mass Spectrometry; Midazolam; Middle Aged; Warfarin | 2006 |
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4.
Topics: Adult; Anticoagulants; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Beverages; Clonidine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Food-Drug Interactions; Half-Life; Humans; Male; Midazolam; Stereoisomerism; Vaccinium macrocarpon; Warfarin | 2007 |
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Caffeine; Chlorzoxazone; Coumarins; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Mephenytoin; Metoprolol; Midazolam; Middle Aged | 2007 |
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Anticoagulants; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Humans; Male; Metabolic Clearance Rate; Midazolam; Omeprazole; Warfarin; Young Adult | 2009 |
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Topics: Adult; Antiviral Agents; Aryl Hydrocarbon Hydroxylases; Cyclopropanes; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Midazolam; Middle Aged; Proline; Ritonavir; Sulfonamides; Vitamin K; Warfarin; Young Adult | 2013 |
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Nitriles; Omeprazole; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Theophylline; Warfarin; Young Adult | 2014 |
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Hepatitis C; Humans; In Vitro Techniques; Isoenzymes; Leucine; Male; Microsomes, Liver; Midazolam; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Thiazoles; Warfarin; Young Adult | 2015 |
Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Topics: Adult; Animals; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Fasting; Gene Expression Regulation, Enzymologic; Humans; Liver; Male; Metabolic Clearance Rate; Metoprolol; Midazolam; Omeprazole; Rats, Wistar; Warfarin; Young Adult | 2015 |
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Warfarin; Young Adult | 2015 |
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
Topics: Administration, Intravenous; Administration, Oral; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Combinations; Fasting; Healthy Volunteers; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Time Factors; Warfarin; Young Adult | 2017 |
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Caffeine; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Omeprazole; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Tandem Mass Spectrometry; Warfarin | 2018 |
Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
Topics: Administration, Intravenous; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Fasting; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Protein Binding; Warfarin | 2018 |
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Injections, Subcutaneous; Interleukin-23 Subunit p19; Male; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Treatment Outcome; Warfarin; Young Adult | 2018 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Injections, Subcutaneous; Male; Midazolam; Omeprazole; Psoriasis; Severity of Illness Index; Substrate Specificity; Warfarin | 2019 |
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Male; Midazolam; Middle Aged; Omeprazole; Phenotype; Vitamin K; Warfarin | 2020 |
Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Drug Interactions; Germany; Humans; Isoenzymes; Male; Midazolam; Middle Aged; Mineralocorticoid Receptor Antagonists; Models, Biological; Naphthyridines; Piperidines; Substrate Specificity; Warfarin; Young Adult | 2020 |
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Warfarin; Young Adult | 2020 |
Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Mineralocorticoid Receptor Antagonists; Warfarin; Young Adult | 2020 |
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Lung Neoplasms; Male; Midazolam; Middle Aged; Pyrimidines; Sulfones; Warfarin; Young Adult | 2021 |
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants.
Topics: Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Niacinamide; Piperidines; Pyrazoles; Warfarin | 2022 |
51 other study(ies) available for midazolam and warfarin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.
Topics: Animals; Antimalarials; Benzimidazoles; Life Cycle Stages; Malaria; Male; Mice; Plasmodium berghei; Structure-Activity Relationship | 2017 |
Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Caenorhabditis elegans; Carbanilides; Drug Resistance, Bacterial; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Staphylococcus aureus; Vancomycin Resistance | 2017 |
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
Topics: Administration, Oral; Aminopyridines; Aminoquinolines; Animals; Antimalarials; Cell Membrane Permeability; Chloroquine; CHO Cells; Cricetulus; Drug Evaluation, Preclinical; Drug Resistance, Microbial; ERG1 Potassium Channel; Hemeproteins; Humans; Malaria; Male; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Solubility; Structure-Activity Relationship | 2017 |
Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase.
Topics: Anticoagulants; Antineoplastic Agents, Hormonal; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Carcinogens; Cell Division; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diuretics, Osmotic; GABA Modulators; Gene Expression Regulation, Enzymologic; Genetic Vectors; Humans; Indoles; Mammary Tumor Virus, Mouse; Mannitol; Microscopy, Electron; Microsomes; Midazolam; Mixed Function Oxygenases; Nifedipine; Oxidoreductases; Propranolol; Pyridines; Sympatholytics; Testosterone; Tetradecanoylphorbol Acetate; Transfection; Tritium; Warfarin | 1999 |
High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Chlorzoxazone; Coumarins; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2E1 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Single-Blind Method; Specimen Handling; Spectrometry, Mass, Electrospray Ionization; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Substrate Specificity; Tolbutamide | 2001 |
Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Topics: Alkylating Agents; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Ethanolamines; Genetic Engineering; Humans; Midazolam; Mixed Function Oxygenases; Mutagenicity Tests; NADP; NADPH-Ferrihemoprotein Reductase; Nitrosamines; Recombinant Proteins; Salmonella typhimurium; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 2001 |
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Baculoviridae; Cells, Cultured; Chlorzoxazone; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; DNA, Complementary; Ethanolamines; Gene Expression; Humans; Insecta; Isoenzymes; Mephenytoin; Midazolam; Nitrophenols; Pharmaceutical Preparations; Phenacetin; Rats; Substrate Specificity; Testosterone; Tumor Cells, Cultured | 2002 |
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Topics: Alprazolam; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clarithromycin; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; Diltiazem; Estradiol; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Midazolam; Nifedipine; Tamoxifen; Testosterone; Triazolam | 2002 |
Systematic evaluation of complications related to endoscopy in a training setting: A prospective 30-day outcomes study.
Topics: Aged; Anticoagulants; Clinical Competence; Endoscopy, Gastrointestinal; Female; Gastroenterology; Hospitals, University; Humans; Hypnotics and Sedatives; Internship and Residency; Male; Midazolam; Patient Satisfaction; Postoperative Complications; Prospective Studies; Risk Factors; Surveys and Questionnaires; Treatment Outcome; Warfarin | 2003 |
A high-throughput method for enzyme kinetic studies.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, Liquid; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; Drug Evaluation, Preclinical; Enzyme Inhibitors; Enzymes; Half-Life; Humans; Kinetics; Mass Spectrometry; Midazolam; Molecular Biology; Sensitivity and Specificity; Testosterone; Warfarin | 2003 |
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Induction; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Lopinavir; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pyrimidinones; Ritonavir; Substrate Specificity; Warfarin | 2006 |
Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes.
Topics: Animals; Biological Transport; Coumarins; Cryopreservation; Diffusion; Drug Evaluation, Preclinical; Hepatocytes; Humans; In Vitro Techniques; Kinetics; Metabolic Clearance Rate; Microsomes, Liver; Midazolam; Phenacetin; Propranolol; Rats; Reproducibility of Results | 2006 |
Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes.
Topics: Amino Acid Sequence; Animals; Baculoviridae; Base Sequence; Blotting, Western; Cell Line; Cloning, Molecular; Coumarins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Humans; Ketoconazole; Kinetics; Liver; Macaca mulatta; Microsomes, Liver; Midazolam; Molecular Sequence Data; Nifedipine; Recombinant Proteins; Sequence Analysis, DNA; Spodoptera; Substrate Specificity; Testosterone | 2006 |
Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Drug Design; Drug Interactions; Enzyme Inhibitors; Ethanolamines; Fluorescent Dyes; Humans; In Vitro Techniques; Isoenzymes; Kinetics; Liver; Microsomes, Liver; Midazolam; Recombinant Proteins; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Substrate Specificity; Tandem Mass Spectrometry | 2007 |
[Present conditions of pediatric pharmacotherapy--data network model research in pediatric pharmacotherapy].
Topics: Adjuvants, Anesthesia; Adolescent; Anticoagulants; Child; Child, Preschool; Databases, Factual; Dosage Forms; Drug Administration Schedule; Drug Information Services; Drug Therapy; Humans; Infant; Infant, Newborn; Midazolam; Pediatrics; Warfarin | 2008 |
Midazolam suppresses interleukin-1β-induced interleukin-6 release from rat glial cells.
Topics: Animals; Anthracenes; Cells, Cultured; Coumarins; Enzyme Inhibitors; Flavonoids; GABA Modulators; Humans; Hypnotics and Sedatives; Interleukin-1beta; Interleukin-6; Midazolam; Mitogen-Activated Protein Kinases; Neuroglia; Propofol; Rats; STAT3 Transcription Factor | 2011 |
Evaluation of food-drug interaction of guava leaf tea.
Topics: Animals; Beverages; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Food-Drug Interactions; Humans; Liver; Male; Midazolam; Partial Thromboplastin Time; Polyphenols; Psidium; Rats; Rats, Sprague-Dawley; Warfarin | 2013 |
Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; Intestine, Small; Liver; Microsomes; Microsomes, Liver; Midazolam; Solvents; Warfarin | 2012 |
Predicted metabolic drug clearance with increasing adult age.
Topics: Adult; Aged; Aged, 80 and over; Aging; Caffeine; Computer Simulation; Desipramine; Female; Humans; Male; Mephenytoin; Metabolic Clearance Rate; Midazolam; Middle Aged; Models, Biological; Warfarin | 2013 |
Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs.
Topics: Administration, Oral; Animals; Biological Availability; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Metoprolol; Midazolam; Models, Animal; Omeprazole; Substrate Specificity; Swine; Swine, Miniature; Tandem Mass Spectrometry; Warfarin | 2012 |
The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel.
Topics: Complementary Therapies; Coumarins; Cytochrome P-450 CYP3A; Docetaxel; Ginkgo biloba; Grape Seed Extract; Humans; Microsomes, Liver; Midazolam; Silybum marianum; Taxoids; Tea | 2014 |
Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation.
Topics: Administration, Oral; Age Factors; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Metoprolol; Microsomes, Liver; Midazolam; Models, Animal; Models, Biological; Omeprazole; Warfarin | 2015 |
Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.
Topics: Administration, Intravenous; Administration, Oral; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Macaca fascicularis; Microsomes, Liver; Midazolam; Models, Biological; Omeprazole; Pharmacokinetics; Warfarin | 2015 |
Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Caffeine; Callithrix; Chromatography, Liquid; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Intestine, Small; Liver; Metoprolol; Midazolam; Models, Animal; Omeprazole; Tandem Mass Spectrometry; Warfarin | 2016 |
Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling.
Topics: Animals; Cytochrome P-450 Enzyme System; Dogs; Humans; Metoprolol; Midazolam; Models, Biological; Omeprazole; Swine; Swine, Miniature; Warfarin | 2016 |
Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling.
Topics: Animals; Caffeine; Chimera; Cytochrome P-450 Enzyme System; Dogs; Humans; Macaca fascicularis; Mice; Midazolam; Models, Biological; Omeprazole; Pharmaceutical Preparations; Pharmacokinetics; Swine; Swine, Miniature; Warfarin | 2016 |
Micropatterned coculture of hepatocytes on electrospun fibers as a potential in vitro model for predictive drug metabolism.
Topics: Animals; Cells, Cultured; Coculture Techniques; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Endothelial Cells; Fibroblasts; Hepatocytes; Male; Microscopy, Confocal; Microscopy, Electron, Scanning; Midazolam; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Tolbutamide; Warfarin | 2016 |
Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
Topics: Animals; Caffeine; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Fasting; Female; Gene Expression Regulation; Inactivation, Metabolic; Liver; Membrane Proteins; Metoprolol; Mice; Mice, Inbred C57BL; Mice, Knockout; Midazolam; Omeprazole; Receptors, Cytoplasmic and Nuclear; Warfarin | 2016 |
The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates.
Topics: Computer Simulation; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dextromethorphan; Diclofenac; Drug Interactions; Female; Hepatocytes; Humans; Hydrogen-Ion Concentration; Kinetics; Male; Midazolam; Plasma; Testosterone; Warfarin | 2017 |
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin | 2018 |
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Chenodeoxycholic Acid; Cholangitis; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Omeprazole; Rosuvastatin Calcium; Warfarin | 2017 |
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Double-Blind Method; Drug Interactions; Enzyme Induction; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Oxadiazoles; Rifampin; Warfarin; Young Adult | 2017 |
Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P450 Family 2; Drugs, Chinese Herbal; Enzyme Activation; Herb-Drug Interactions; Isoenzymes; Midazolam; Omeprazole; Rats; Steroid 16-alpha-Hydroxylase; Tolbutamide; Warfarin | 2017 |
Predicted contributions of cytochrome P450s to drug metabolism in human liver microsomes using relative activity factor were dependent on probes.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Diclofenac; Humans; Kinetics; Microsomes, Liver; Midazolam; Protein Isoforms; Testosterone; Tolbutamide; Verapamil; Warfarin | 2019 |
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
Topics: Administration, Oral; Adult; Caffeine; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Dextromethorphan; Down-Regulation; Drug Development; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Models, Biological; Neuromyelitis Optica; Omeprazole; Rare Diseases; Serum Albumin, Human; Simvastatin; Warfarin | 2019 |
Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation.
Topics: Adult; Asian People; Computer Simulation; Cytochrome P-450 Enzyme System; Female; Glucuronosyltransferase; Humans; Liver-Specific Organic Anion Transporter 1; Lorazepam; Male; Metoprolol; Midazolam; Middle Aged; Models, Biological; Omeprazole; Rosuvastatin Calcium; Software; Warfarin; Young Adult | 2019 |
Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseases.
Topics: Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Warfarin | 2022 |
Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Warfarin | 2023 |